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Abstract 
Diabetic retinopathy (DR) is a microvascular complication associated with 
Diabetes mellitus (DM) and the leading cause of blindness in developed countries. 
Hyperglycemia and hypoxia are suggested to play essential pathophysiological role in the 
onset, progression and prognosis of DR. Moreover, hypoxia inducible factor-1 (HIF-1), 
which is stabilized under hypoxic conditions, acts as a transcription factor of several genes 
such as vascular endothelial growth factor (VEGF) and glucose transporter 1 (GLUT1). It 
was also described that an imbalance between pigment epithelium-derived factor (PEDF), 
a potent angiogenic inhibitor, and VEGF, the major angiogenic stimulator, is present in 
patients that suffer of DR. However little is known about the role of this imbalance in DR 
progression. 
Therefore the goal of this study was to characterize the expression of GLUT1, pro-, 
and anti-angiogenic factors involved in the development and progression of DR, using in 
vitro and in vivo models of the disease.  
The present study demonstrates that in D407 cells, an immortalized retinal 
pigmented epithelium (RPE), the levels of the glucose transporter GLUT1 are increased in 
the response to hypoxia and hyperglycemia and this increase is more pronounced in the 
cell membrane fraction. Additional support to our in vitro results is the fact that GLUT1 
expression levels are increased in Ins2
Akita
 mice, a model of type 1 DM. 
Regarding PEDF expression in vitro, there was no significant difference between 
tested conditions, but we observed the tendency to decrease in hypoxic conditions. In vivo, 
we could see a significant decrease of PEDF expression in the retina of 6 month-old mice; 
but the key result is the marked decrease detected in the RPE cell layer. VEGF mRNA 
levels were increased in vitro and in vivo at 6 month-old animals, but this was not observed 
for the protein levels. At 12 months of age, mRNA levels were similar in WT and diabetic 
mice, but the protein levels are significantly decreased in diabetic mice, a potential 
consequence of the overall senescence observed for these animals. 
 Taken together, these results suggest that the increase in GLUT1 and the decrease 
in PEDF expression levels are associated with the development of diabetic retinopathy. 
 
Keywords: Diabetic retinopathy (DR); hypoxia; hyperglycemia; vascular 
endothelial growth factor (VEGF); glucose transporter 1 (GLUT1); pigment epithelium-
derived factor (PEDF); 
 Liliana Alves                                                                              Masters in Biomedical Sciences 
  
vii 
Resumo 
A retinopatia diabética (DR) é uma complicação microvascular da retina que causa 
cegueira a mais de 10 000 pessoas diabéticas anualmente. Esta doença resulta da exposição 
prolongada da retina a elevados níveis de glucose resultantes do estado diabético.  
Os processos envolvidos no desenvolvimento das complicações associadas à 
diabetes são ainda desconhecidos, no entanto pensa-se que estas poderão estar associadas a 
uma maior captação da glucose por parte da retina e a uma exposição prolongada à hipóxia 
que leva à neovascularização da retina.  
A glucose é transportada na barreira hemato-retiniana através do transportador 
GLUT1, que é regulado pela concentração sanguínea de glucose e pelo fator indutor de 
hipóxia, HIF-1. O HIF-1 tem um papel importante em condições de hipoxia pois funciona 
como factor de transcrição de vários genes importantes como o VEGF, que é o principal 
potenciador da neovascularização. Também foi descrito que pacientes que sofrem DR 
possuem um desequilíbrio entre os fatores pro-angiogénicos e anti-angiogénicos como o 
VEGF e o PEDF, respetivamente.  
Com base nestes dados, este trabalho teve como objetivo avaliar os níveis de 
expressão do transportador GLUT1 e dos fatores VEGF e PEDF em sistemas in vitro de 
células da retina D407 em condições de hipóxia e normóxia sujeitas a diferentes 
concentrações de glucose. Foi ainda avaliada a expressão do GLUT1 e dos fatores VEGF e 
PEDF in vivo, em amostras de retina de ratinhos Ins2
Akita
, um modelo animal de DM tipo I, 
que apresenta algumas características da DR, e em amostras de animais “wild type” não 
diabéticos. Esta avaliação foi feita ainda em dois momentos na vida dos ratinhos: aos 6 
meses de idade, que representa o início do desenvolvimento da doença em que começa a 
mostrar alguns sintomas característicos de DR, como microaneurismas e vazamento 
vascular, e aos 12 meses de idade, que representa um estádio crónico da doença.  
Os resultados mostram in vitro, nas células RPE imortalizadas D407 um aumento 
do transportador GLUT1 quando estas são sujeitas a condições de hiperglicemia e hipóxia. 
Mas o que se destacou foi o facto de este aumento ser mais predominante nas membranas 
das células o que sugere que há um aumento não só da concentração como também da sua 
translocação para a membrana celular. 
Em relação aos níveis de expressão do PEDF in vitro apesar de esta diminuição não 
ser significativa, apresenta tendência para diminuir em condições de hipóxia. Contudo, nos 
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níveis de expressão do VEGF in vitro não se verificou qualquer alteração nas condições 
testadas. 
Nos resultados in vivo podemos verificar que houve um aumento da expressão do 
transportador GLUT1 na retina de ratinhos Ins2
Akita
 em comparação com os ratinhos “wild 
type” de 6 meses de idade, sugerindo que este aumento dos transportadores poderá estar 
associado ao desenvolvimento de DR em estádios precoces da doença. Já aos 12 meses 
este aumento não é significativo o que poderá estar associado à senescência que a retina 
apresenta nesta idade. 
 Em relação ao PEDF in vivo, podemos constatar que em amostras de retina e de 
epitélio pigmentar da retina (RPE) de ratinhos de 6 meses houve uma diminuição 
significativa na sua expressão aos 6 meses de idade. Já aos 12 meses essa expressão foi 
abolida na RPE dos ratinhos diabéticos. 
Por último, os níveis de expressão do VEGF in vivo são controversos pois podemos 
verificar um aumento da expressão do mRNA nas retinas dos ratinhos Ins2
Akita
, aos 6 
meses de idade, mas não da proteína. Porém, aos 12 meses não se verificou alteração dos 
níveis de mRNA entre estirpes mas sim uma diminuição da expressão proteica que pode 
estar associado ao estádio avançado da doença nos ratinhos Ins2
Akita
. 
O nosso estudo sugere que o GLUT1 e o PEDF podem ser componentes 
importantes para o desenvolvimento de DR, sendo este último mais importante no estádio 
inicial da doença. 
 
Palavras-chave: Retinopatia diabética (RD); Hipóxia; Hiperglicemia; GLUT1; 
VEGF; PEDF; células D407; Ins2
Akita
. 
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1. Introduction 
1.1 Diabetes 
In the last decades, scientists have been searching for a cure or an efficient treatment 
for diabetes, an epidemic disease that is growing in an alarming rate. 
[1]
 Although some 
treatments like drug therapy combined with advanced technology and prevention measures 
seem to be effective, the battle to halt this growing is being lost. 
International diabetes federation (IDF) announced that in 2014, 382 million people 
have diabetes and are expected to rise more 205 million by 2035. 
[2]
 More concerning is the 
fact that Portugal is the country with the highest prevalence of diabetes (13.09%) from all 
Europe besides Turkey (14.71%). 
[3]
 Associated with the increase of diabetic population is 
the increase of health expenditures. In 2013, the global health spending to treat diabetes 
complications was about 581 billion of International Dollars (ID) and is expected to 
increase to almost ID 678 billion in 2035. In other words, it was spent on average ID 1,522 
per person in 2013. 
[2]
 
The main problem in this century is the increase of risk factors associated with diabetes 
like obesity, sedentary lifestyle, smoking, alcohol and unhealthy diet. 
[4]
 Since diabetes is 
one of the most non-communicable diseases (NCDs) and one of the leading cause of death, 
the associated complications are of paramount importance for the population. 
[2] [5]
 
Diabetes Mellitus (DM) is a metabolic disease characterized by chronic hyperglycemia 
resulting from defects in insulin secretion, insulin action or both. The majority of cases of 
DM fall into two broad categories designated type 1 (T1DM) and type 2 (T2DM) but there 
are other types of DM like gestational diabetes (GDM) or DM derived from genetic 
defects. Both T1DM and T2DM are preceded by a phase of abnormal glucose homeostasis 
as the disease progresses. While T1DM is a result of an absolute or near-total insulin 
deficiency, T2DM is a group of disorders characterized by variable degrees of insulin 
resistance, impaired insulin secretion and increased glucose production. 
[6]
 
[7]
  
T1DM also known as insulin-dependent diabetes results from a cellular mediated 
autoimmune destruction of the pancreatic β-cells and corresponds only to 5-10% of those 
with diabetes. 
On the other hand, T2DM or non-insulin dependent diabetes includes individuals who 
have insulin resistance and relative insulin deficiency. It is estimated that 90-95% of those 
with diabetes have this type and they do not need insulin treatment to survive. Most of the 
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T2DM diabetic patients are obese which can cause some degree of insulin resistance itself. 
[6] [7]
 
Long term complications of diabetes are associated with chronic hyperglycemia 
exposure. Generally, hyperglycemia effects on the body can be separated into 
macrovascular (injury in large blood vessels) and microvascular (injury in small blood 
vessels) complications. The macrovascular complications include coronary artery disease, 
peripheral arterial disease, and stroke, while microvascular complications include diabetic 
nephropathy, neuropathy, and retinopathy. 
[8]
  
Among the diabetic complications, this work will focus in the diabetic retinopathy, one 
of the most common microvascular complications. 
[8]
 
 
1.2 Retina and BRB 
The retina is a tissue that allows us to see the world. The function of the retina is to 
convert light signal into neural signal and send it to the brain through the optic nerve. To 
understand pathological changes in diabetic retinopathy it is important to know about its 
morphology and physiology. The retina is the innermost layer of three layers of the eye and 
is composed by two sub-layers, the neural retina and retinal pigmented epithelium (RPE), 
which are surrounded by the choroid and the humor vitreous (fig. 1.1). 
[9] 
The two sub-
layers have distinct functions and physiologies. 
 The RPE layer consists of cuboidal cells that surround the neural retina and acts as 
a barrier that absorbs scattered light, regulates the ion transport between the retina and the 
choroid, removes the free radicals and is essential to the visual cycle. 
[9]
 
 The neural retina is composed by five neural cells (photoreceptors, bipolar cells, 
ganglion cells, horizontal cells and amacrine cells) that are disposed by nine layers (fig. 
1.1). 
[10]
 The nine layers (from choroid to vitreous body) are: 
1. Rod and cone layer (RCL) – photoreceptors with different properties. While rods 
have low spatial resolution and are extremely sensitive to light, cones has high 
spatial resolution and are relatively insensitive to light. Therefore rods are 
specialized for sensitivity and cones are specialized for acuity and also responsible 
for color perception. 
[11]
 
2. Outer limiting layer (OLL) – a natural barrier between the sub retinal space and 
outer nuclear layer, localized between the photoreceptors and Müller cell processes. 
[9]
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3. Outer nuclear layer (ONL) - contains cell bodies of the photoreceptors. [9] 
4. Outer plexiform layer (OPL) - includes axons of the photoreceptors and dendrites 
of association neurons in the inner nuclear layer.
 [9]
 
5. Inner nuclear layer (INL) - contains the nuclei of various neurons, specially the 
bipolar cells, amacrine cells, and horizontal cells.
 [9]
 
6. Inner plexiform layer (IPL) - consists of axons and dendrites that connect neurons 
of the INL with the ganglion cells.
 [9]
 
7. Ganglion cell layer (GCL) - contains cell bodies of ganglion cells. [9] 
8. Nerve fiber layer (NFL) – formed by axons of the ganglion cells, that composes the 
optic nerve.
 [9]
 
9. Inner limiting layer (ILL) - consists of terminal expansions of other Müller cell 
processes that cover the collagenous membrane of the vitreous body.
 [9]
 
Figure 1.1: Histological section of the human retina showing the retinal layers with 
hematoxylin/eosin staining. 1: RPE; 2: RCL; 3: OLL; 4: ONL; 5: OPL; 6: INL; 7: IPL; 8: 
GL; 9: NFL; 10: ILL; C - choroidal vascular layers; BM: Bruch’s membrane; VB – 
Vitreous body. Adapted from 
[12]
. 
 
1.3 Diabetic Retinopathy 
1.3.1 Clinical Aspects 
Diabetic retinopathy (DR) is considered the leading cause of blindness in working-age 
adults. 
[2]
 The prevalence of DR after 20 years of DM diagnosis is higher 90% for patients 
with T1DM and > 60% of those with T2DM. 
[13]
  
VB  
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DR is a retinal microvascular disorder that occurs as a complication of DM and is 
characterized by signs of retinal ischemia like microaneurysms, hemorrhages, cotton-
woolspots, intraretinal microvascular abnormalities, venous caliber abnormalities, 
neovascularization and increased retinal vascular permeability. These pathological changes 
in the retinal microvasculature are the result of chronic exposure to elevated blood glucose. 
[14]  [15]
 In addition, some studies showed that after the blood glucose levels have returned to 
normal, the retinal lesions persisted meaning that an early detection is crucial to an 
effective treatment. 
[16]
  
There are two types of DR: non-proliferative DR (NPDR) and proliferative DR (PDR). 
NPDR occurs when there are only intraretinal microvascular changes, such as altered 
retinal vascular permeability and eventual retinal vessel and capillary closure. 
[17]
 In the 
non-proliferative phase, retinopathy is categorized further into four levels of severity: mild, 
moderate, severe, and very severe (described in Table 1.1). 
Neovascularization is not an element of this phase however, in advanced NPDR, 
nonperfusion of the retina and retinal ischemia may be developed and lead to the 
proliferative phase. 
[17]
 
PDR is characterized by neovascularization responding to hypoxic mechanisms.  These 
new vessels, which grow up near the optic disc, break easily leading often to vitreous 
hemorrhage, fibrous bands and retinal detachment leading to blindness. 
[18] 
Table 1.1: Classification of the severity of non-proliferative diabetic retinopathy. 
Adapted from 
[17]
. 
Levels of Severity Lesions Present 
No retinopathy No retinal lesions 
Mild Mild levels of microaneurysms and intraretinal hemorrhage 
Moderate Moderate levels of microaneurysms and intraretinal hemorrhage 
Severe 
Presence of one of the following features: 
1. Severe intraretinal hemorrhage in all 4 quadrants; 
2. Venous beading in 2 or more quadrants; 
3. Moderate intraretinal microvascular abnormalities in at least 1 
quadrant. 
Very severe 
Presence of two or more of the above-mentioned features 
described in severe non-proliferative diabetic retinopathy 
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1.3.2 Pathways of hyperglycemia-induced damage 
It has been proposed several biochemical mechanisms relating hyperglycemia and 
retinal microvascular complications such as polyol pathway, advanced glycation end 
products (AGEs) accumulation, protein kinase C (PKC) activation and oxidative stress 
(Fig. 1.2). 
[19]
 
Figure 1.2: Pathophysiology of DR. Hyperglycemia instigates a cascade of events leading 
to retinal vascular endothelial dysfunction. Adapted from 
[20]
. 
 
1.3.2.1  Polyol Pathway 
Several studies show that polyol pathway may be a plausible contributor to DR and 
other complications. This pathway is highly active under hyperglycemia conditions and 
consists in reducing glucose to sorbitol which is then converted to fructose (fig. 1.3). 
Aldose reductase (AR), the first and rate-limiting enzyme of the pathway, is present in all 
cells types (neurons, Müller glia, pericytes, and endothelial cells) that are affected by 
diabetes. 
[21]
 
The effects of this pathway are variable. Sorbitol is an alcohol, polyhydroxylated and 
strongly hydrophilic contributing to its intracellular accumulation in the cells which 
consequently increase the osmotic stress/pressure. 
[22]
 
Oxidative stress, PKC activation and AGEs production are other effects of polyol 
pathway.  
Hyperglycemia 
Sorbitol AGE  PKC Activation Oxidative stress 
Vascular dysfunction 
Retinal 
neovascularization 
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The fructose produced by the polyol pathway can enter in the formation of fructose-3-
phosphate and 3-deoxyglucosone which are powerful glycating agents and AGE 
precursors. 
[22]
 
It is also known that reactive oxygen species (ROS) can work both as signaling and 
damaging molecules which triggers pro-inflammatory responses as well as apoptosis. So it 
may be expected that chronic activity of polyol pathway in diabetes is sufficient to initiate 
the oxidative stress that is observed in the diabetic retina and should be partly responsible 
for cellular changes that have the potential to shape the development and progression of 
DR (fig. 1.2). 
[22]
  
Figure 1.3: Effects of polyol pathway activation. Increased of cytosolic glucose causes 
accelerated transformation of glucose to sorbitol by aldose reductase (AR). In the second 
step of the polyol pathway, sorbitol is oxidized to fructose by sorbitol dehydrogenase 
(SDH). Finally, fructose produced in the second step of the polyol pathway is a precursor 
of AGEs. Adapted from 
[22]
. 
 
1.3.2.2  AGEs Accumulation 
Some patient-based studies have demonstrated that the levels of AGEs in serum are 
correlated with the clinical progression of DR. 
[23]
 
Non-enzymatic glycation reactions between reducing sugars and the free amino groups 
on proteins, lipids, and DNA are inevitable but in the presence of high levels of glucose 
these reactions are enhanced. 
[24]
 
Thus, over time, even middle hyperglycemia can lead to a significant adduct 
accumulation of AGEs on long-lived macromolecules. 
[24]  [23]
 
 Some studies have demonstrated that AGEs induce toxic effects on retinal pericytes by 
causing oxidative stress and subsequent apoptosis. In addition, other studies have indicated 
that AGEs cause osteoblast differentiation and calcification in retinal pericytes, which 
eventually also leads to apoptosis. Thus, both events may contribute to pericyte loss in the 
retinal capillaries that are present in DR (fig. 1.2). 
[24]
  
 
 
Glucose Sorbitol Fructose 
AR SDH 
AGE 
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1.3.2.3 PKC activation 
In DR, PKC mediates changes in endothelial permeability, blood flow, and both the 
formation and response to angiogenic growth factors contributing to retinal leakage, 
ischemia, and neovascularization. PKC activation also contributes to loss of capillary 
pericytes, an early feature of DR (fig. 1.4). 
[25]
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: PKC, especially PKCβ, mediated phosphorylation of transcription factors, 
cytoskeletal proteins, enzymes and transporters leads to many of the pathophysiological 
features of DR. Adapted from 
[25]
. 
 
The PKC molecule is part of a serine/threonine kinase family that catalyzes 
phosphorylation of key proteins involved in signal transduction. It has individual isozymes 
that are activated by diacylglycerol (DAG), a molecule that is upregulated in vascular 
tissues by hyperglycemia. Differences in structure and substrate requirements allowed to 
identify approximately 12 different PKC isoforms in which PKCβ is the one that 
demonstrates the most significant increase in hyperglycemia. 
[26]
  
PKC has also been implicated in the stimulation of vascular endothelial growth factor 
(VEGF) expression, an important angiogenic factor that will be further discussed in this 
work. 
[27]  
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1.3.2.4 Oxidative Stress 
Oxidative stress is the cytopathic consequence of the generation of excess ROS beyond 
the capacity of a cell to defend against them. It represents an imbalance between the 
production of oxidants and antioxidant defense leading to potential tissue damage.
[28]  [29]
 
Formation of ROS is increased in hyperglycemia by several events and sources of ROS 
such as disruption of the mitochondrial electron transport chain, formation of AGEs 
products, auto-oxidation of glucose, flux through the polyol pathway, uncoupling of nitric 
oxide synthase (NOS), and activation of PKC.
 [29]
 
Moreover, chronic exposure to oxidative stress can induce damage to biological 
macromolecules such as DNA, lipids, proteins, carbohydrates, disruption in cellular 
homeostasis and generation of other ROS which creates further damage in the retina. 
[28]
 
The retina has several defense mechanisms to minimize oxidative stress such as 
glutathione, vitamins A, C, E, and enzyme systems like superoxide dismutase, catalase, 
glutathione reductase (GR) and glutathione peroxidase.
[29]
 
High activity is required to protect the retinal neurons and particularly rod outer 
segments from oxidative stress due to their high metabolism, which leads to a substantially 
less antioxidant activity in the retinal microvascular endothelial cells. Then, this imbalance 
in the endothelial cells may be the explanation for the oxidative stress in retinal capillaries 
under diabetic conditions (fig. 1.2). 
[29]
 
1.3.3 Pathophysiological Process 
All the biochemical mechanisms described above may induce clinical changes in the 
retina that characterizes DR namely pericyte loss, blood retinal barrier (BRB) breakdown, 
inflammation, apoptotic response and neovascularization. 
 
1.3.3.1  Pericyte loss 
Pericytes are the supporting cells of the microvasculature and regular components of 
capillaries in almost all human tissues and organs associated mostly with stabilization and 
hemodynamic processes of blood vessels. Pericytes in the retina are completely embedded 
within the capillary basement membrane (BM), surrounding the endothelial cells (ECs) 
originating the capillary tube. The density of pericyte coverage in the capillary varies from 
organ to organ but the highest density is found in the retinal microvasculature. One 
explanation for the high pericyte coverage of capillaries of the retina is the function of 
blood vessels in this specialized organ. The blood supply to the retina is the highest among 
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all organs of the body and the need for vessel tightness is particularly high in the retina for 
proper visual function. Therefore, the greater the number of pericytes covering the EC 
tube, the better the barrier functions. 
[30]
 
Some studies show that pericyte possesses contractile properties and control capillary 
blood flow in response to local modulation by vasoactive mechanisms, but the most 
prominent function is their role in vascular growth and vessel stabilization. 
[30]
 
Moreover, pericytes loss in DR consequently alters the blood flow in the retinal 
capillaries which can lead to capillary leakage, vessel occlusion and ultimately 
microaneurysms formation. 
[31]
 Furthermore, pericyte loss destabilizes the BRB integrity, 
making it more permeable. Due to these consequences, pericyte loss is one of the earliest 
changes in DR. 
[30]
 
 
1.3.3.2  Inflammation in DR 
Most of the metabolic and physiologic abnormalities found in DR are consistent with 
the presence of a chronic inflammation which may play a critical role in the development 
of the early and late stages of the disease. 
[32]
  
Inflammation is a signal-mediated response to cellular insult that embraces a variety of 
functional and molecular mediators, including recruitment and/or activation of leukocytes. 
While acute inflammation has beneficial effects against those insults, chronic inflammation 
can cause undesirable effects like tissue destruction. 
[33]
 
Some studies have shown that DR is associated with increase of inflammatory markers 
like leukocytes, cytokines, interleukins, platelets, intercellular adhesion molecules and 
growth factors. Whether the presence of this inflammatory markers in DR is due to the 
vasculopathy or whether they are directly involved in the damage is not yet elucidated. 
[34]
  
Nevertheless, leukostasis, a major component of inflammatory process, contribute to 
capillary non-perfusion and has been postulated to be a factor in endothelial cell deaths and 
breakdown of the BRB. Diabetic retinal vascular leakage, capillary non-perfusion, and 
endothelial cell damage are associated with leukocyte recruitment and adhesion to the 
retinal vasculature which correlate with increased expression of inflammatory markers. 
[35] 
Therefore, these inflammatory markers are important in the development of early 
stages of DR.  
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1.3.3.3  BRB breakdown 
Another important structure present in the retina is BRB. It is an important barrier that 
is essential to maintain the function and structure of the retina. It controls fluid and 
molecular movement between the ocular vascular beds and the retinal tissues and prevents 
leakage into the retina of macromolecules and other potentially harmful agents. 
It consists of two layers, the inner BRB (iBRB) and outer BRB (oBRB) (Fig. 1.5). The 
iBRB is formed by tight junctions between ECs from neighboring capillaries and the 
oBRB is composed by tight junctions between RPE cells. 
[36]
 The BRB maintenance is 
covered by the foot processes of astrocytes, Müller cells and pericytes that contribute to a 
proper BRB functioning and integrity. 
The BRB breakdown present in DR is characterized by an increased vascular 
permeability, which comes from molecular changes in proteins of the tight junctions 
complex and loss of pericytes. Ultimately, BRB breakdown leads to microaneurysms and 
neovascularization. 
[37]
 
Figure 1.5: Schematic diagram of the inner and outer blood–retinal barrier and its location 
in the retina. The retinal cell layers seen histologically consist of RPE cells, photoreceptor 
outer segments (POS=RCL); outer limiting “membrane” (OLM); outer nuclear layer 
(ONL); outer plexiform layer (OPL); inner nuclear layer (INL); inner plexiform layer 
(IPL); ganglion cell layer (GCL); nerve fiber layer (NFL); inner limiting “membrane” 
(ILM). Adapted from 
[38]
. 
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1.3.3.4 Capillary Dropout and Neovascularization 
Capillary dropout is characterized by the loss of capillary components like pericytes 
and ECs that causes degeneration, obliteration of capillaries, ischemia, release of 
angiogenic growth factors and eventually retinal neovascularization. 
[39]
 
Capillaries provide nutrients and oxygen to the retina and remove its waste products in 
order to maintain the retinal homeostasis. In general, the high caliber blood vessels are 
localized in the innermost portion of the retina while capillaries are found between the 
nerve fiber and inner nuclear layers. 
[39]
 
In the disease there is loss of pericytes during the initial stages, which is followed by 
the loss of ECs. The small vessels start to bleed and leak to the surrounding tissue and the 
retina become ischemic/ hypoxic. In response, there are release of growth factors leading 
to the growth of new vessels (neovascularization) and occlusion of the pre-existing ones. 
The new blood vessels are abnormal and leaky which may cause microaneurysms. They 
can be intraretinal or extend into the vitreous cavity leading to vitreous hemorrhage and 
ultimately blindness. 
[39] 
 
1.4 Hypoxic Response 
From all the tissues in the human body, retina shows the highest oxygen (O2) 
consumption and metabolic activity. This high consumption is due to the energetic 
requirement of the photoreceptors for the signal
 
transduction. 
[40] 
So, an adequate and 
continuous O2 supply is essential for a good retinal function. 
[41]  [42] 
 
One interesting fact is when the retina is under a systemic hypoxia condition (a non-
ischemic form of O2 deprivation), retinal function is impaired. Therefore, O2 is a limited 
metabolite essential for a normal retinal function. 
[43]
  
Although the retina receives supplies from two separate circulations (retinal and 
choroidal circulation), the photoreceptor layer is avascular and the O2 supply is barely 
enough. 
[44]
 Consequently, when rods operate at maximum activity, hypoxia or, in extreme 
cases, anoxia may develop in the inner portions of the retina in diseases with less than 
optimal O2 supply. 
[40]
 
In DR, the presence of hyperglycemia and capillary dropout may expose retina to a 
pseudo-hypoxia and lately to hypoxia condition that can activate adaptive cell responses. 
One of the responses is the stabilization of hypoxia-inducible factor-1 complex (HIF-1). 
[41]
 
[45] [46] 
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HIF-1 is a heterodimeric nuclear transcription factor composed of two units: an α and a 
β subunit. Both subunits are constitutively expressed in cells but HIF-1α is usually 
degraded under normoxia conditions by specific prolyl hydroxylases (PHDs) that targets 
HIF-1α for proteasome degradation.[41] [45] 
Under hypoxia conditions, HIF-1α is stabilized, dimerises with HIF-1β, and 
translocates to the nucleus, where acts as a transcription factor of a series of genes involved 
in angiogenesis, glycolytic energy metabolism, cell proliferation and survival (Fig. 1.6), 
such as: 
[41]  [45]
 
 [47]
 
 VEGF, involved in angiogenesis,  
 Glucose transporter 1(GLUT1)/ glycolytic enzymes that increases the glucose 
uptake; 
  Erythropoietin (EPO) that is essential for blood cells formation; 
 Insulin-like growth factor-2 (IGF2) and transforming growth factor- α (TGF-α) 
that contributes to cell proliferation.  
Figure 1.6: HIF-1 activity under hypoxia and normoxia conditions. Adapted from 
[47]
. 
The activation of those genes by hypoxia may be the cause of the characteristic 
symptoms visible in DR like abnormal growth of blood vessels and neovascularization and 
aneurysms. Therefore, both hypoxia and hyperglycemia conditions can activate responses 
that drive to DR symptoms.  
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1.5 Factors modified in DR 
To date, several possible mechanisms have been implicated in the development of DR. 
These mechanisms are mostly dependent on excessive transport of glucose into retinal 
cells, which is done by GLUT1. It has been described that this transporter is upregulated 
by hyperglycemia. In hypoxic conditions, as was previously described, HIF-1α is stabilized 
and leads to the transcription of several genes like glut1 and vegf, a potent angiogenic 
factor that is overexpressed in DR and is mostly responsible for the vascular alterations. 
Also, it is known that in DR there is an imbalance between VEGF and PEDF counteracting 
action. 
[16]
 
Therefore, these three factors have an important role in the development of DR. 
 
1.5.1 Glucose transporter 1 (GLUT1) 
Glucose is essential for normal metabolic activity in the neural tissue. Glucose demand 
by the retina is enormous, which means that it is necessary an adequate glucose delivery 
from the circulation to supply all retinal needs. Glucose uptake to the retina is exclusively 
performed through the BRB by sodium-independent glucose transporter GLUT1. 
Therefore, changes in the GLUT1 abundance in the BRB may have profound 
consequences in the glucose delivery to the retina.
 [48]
 
GLUT1 is expressed in high density in erythrocytes and blood-tissue barriers (such as 
BRB) while the remaining GLUTs have other tissue-specific localization. Comparison 
studies among glut1 of various species reveal high levels of conservation (>95%) which 
highlight the critical and universal importance of this transporter in cellular metabolism. 
Other proof of its importance is the fact that GLUT1 expression is detected in various cell 
types of the retina during development as early as 8 weeks of gestation. 
[48]
 
The expression of GLUT1 is regulated/ modulated by several factors such as hypoxia, 
growth factors and glycemia. 
 In cases of DR, the retina is submitted both to hypoxia and hyperglycemia. Under 
hypoxic conditions it is expected that the levels of GLUT1 arises by HIF-1 activation. 
[41]  
However, conflicting studies have been published regarding GLUT1 contribution for the 
development and progression of the disease. While some studies have reported reduction 
of the GLUT1 protein levels in the retina with chronic hyperglycemia 
[49] 
 
[50]
, other studies 
demonstrated an upregulation of the GLUT1 in the early development of DR. 
[14]
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Moreover, it has been shown that VEGF may play indirectly a role in the GLUT1 
expression on DR conditions. Specifically, a study showed that VEGF upregulates the 
translocation of cytosolic GLUT1 to the plasma membrane surface which consequently 
cause an intracellular increase of glucose in retinal cells. 
[51]
 
Therefore, the levels of GLUT1 may vary with the course of the disease.  
1.5.2 Vascular endothelial growth factor (VEGF) 
Recent evidence shows that new vessels growth and maturation are highly complex and 
coordinated processes, requiring a sequential activation of a series of receptors by 
numerous ligands. 
[52]
 
VEGF is not only a potent angiogenic factor and plays a role in normal physiological 
functions such as bone formation, hematopoiesis, wound healing and development, but 
also is a strong vascular permeability enhancer. 
[53]
 VEGF signaling represents a critical 
rate-limiting step in physiological and pathological angiogenesis. 
[52]
 
Its presence is so important that even heterozygous knockout of the vegf gene results in 
embryonic lethality. Also, VEGF is known as a vascular permeability factor based on its 
ability to promote vascular leakage which enhances its importance in other mechanisms 
like inflammation.
[52]
 
Nowadays, the VEGF family comprises seven members: VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F and PLGF (placental growth factor). 
[52]
 
VEGF (also referred to as VEGF-A) has high affinity for two receptors, VEGFR-1 and 
VEGFR-2 both of which are express on vascular ECs. 
[53]
  
Regulation of VEGF expression is made by several factors but the most important are 
the oxygen tension and growth factors. 
[52]
 In DR, due to hypoxia exposure and HIF-1 
activation VEGF levels are increased, as described in several publications. 
[54]  [55]  [56] 
1.5.3 Pigment Epithelium–Derived Factor (PEDF) 
In order to have a normal angiogenic growth, the balance between pro and anti-
angiogenic factors should be tightly controlled. The disruption of this balance plays an 
essential role in the development of diseases. 
[57]
 PEDF was first identified as a 50 kDa 
secreted glycoprotein in conditioned medium from cultured fetal human RPE cells that 
belongs to the serine proteinase inhibitor superfamily. 
[58]
 It displays several biological 
activities such as neurotrophic and neuroprotective properties, anti-vasopermeability, anti-
inflammatory, anti-fibrosis, and anti-cancer activities and function as an endogenous 
inhibitor of angiogenesis. 
[58]
  
[59]
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PEDF was described to inhibit angiogenesis in a number of in vivo assays and the 
decreased levels of PEDF in the vitreous and ocular tissues were associated with PRD and 
choroidal neovascularization. More specifically, it has been shown that PEDF and VEGF 
have a reciprocal interaction and PEDF counteract the angiogenic potential of VEGF 
which means that the increased of one of them leads to a decreased of the other. In other 
words, the VEGF overproduction in DR provokes a decreased production of PEDF which 
subsequently leads to BRB breakdown and neovascularization. 
[59]  [60]
 
Thus, PEDF may play important roles in preventing the development of RD. 
[59]
 
 
1.6 RD Models 
In vivo or in vitro models are important tools for understanding the biological 
mechanisms that are involved in the development of diseases. The in vitro models display 
several advantages over in vivo models like the ability to control the environment, test a 
specific hypothesis, no need of animal sacrifice, faster results and the amount of reagents 
spent are less than in vivo.  
However, there are some disadvantages regarding this system. The environment is not 
precisely equal to the in vivo and due to that, the in vitro models do not behave exactly like 
in vivo. 
So, the in vivo models have the advantage that the tissues are under similar conditions 
to those detected in human. Nevertheless is more expensive and takes more time to obtain 
the results. 
 
1.6.1 In vitro models: D407 cell line 
The RPE cells present in the human eye are part of the oBRB, which controls the 
entrance and exit of substances like nutrients, growth factors and hormones. Extensive 
investigations of human RPE have been limited by the need of using primary cultures. 
Moreover, they rarely survive more than 8 to 10 passages and they often lose their initial 
morphology. 
[61]
 Due to these, investigators seek out for a continuous cell line that would 
keep both the morphology and the function of the RPE. There are several commercially 
available RPE cell lines and the cell line used in this work is D407 cell line. 
D407 cell line retains most of the RPE characteristics which make it possible to study 
potential alterations in the RPE in different conditions. This cell line came from human 
RPE primary culture that was spontaneously transformed and immortalized. The D407 
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cells retain epithelial morphology and possess a keratin-containing cytoskeleton however 
they lose some enzymatic activity and their polarization. 
[61]
 
 
1.6.2 In vivo models: Ins2
Akita
 mouse 
Animal models are being used by numerous groups to study the pathogenesis of DR. 
They remain an essential part to understand the pathogenesis process and to identify 
promising ways to inhibit the retinal disease. There are several RD animal models like 
rodents, primates, cats, dogs which develop the disease by three pathways: born with the 
preposition to develop diabetes, induced by chemicals or develop T2DM by turning them 
obese. 
[62]
 
The common drugs used to induce diabetes are alloxan and streptozotocin (fig. 1.7). 
Although both drugs incite Langerhans isles inflammation and pancreatic β-cells 
destruction, they act differently. While streptozotocin, an alkaline compound, will alkylate 
DNA and consequently fragment it, alloxan will lead to an increase of ROS within the cells 
and its accumulation leads to cell death (Fig. 1.7). 
[63]
 Nevertheless, diabetes induced by 
toxins is becoming less successful because the animal models are becoming more resistant 
to drugs.   
Figure 1.7: Schematic representation of the toxic effects of the glucose analogues 
alloxan and streptozotocin in pancreatic β cells, which produce chemical diabetes. Adapted 
from 
[63]
. 
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So, the study of the Ins2
Akita
 mouse, a spontaneous model for T1DM, is of great 
potential for studying diabetes’ complications including  DR. C57BL/6J Ins2Akita mouse 
descend from heterozygotes male mouse for the Ins2 gene crossed with C57BL/6J wild-
type (WT) females. These mice possess a point mutation in the insulin gene 2 that causes 
the misfolding of insulin protein. This misfolded protein will accumulate in the β cells’ 
endoplasmic reticulum and activate several responses that lead to cell death. From β-cell 
death results hyperglycemia and hipoinsulinemia. These symptoms start to appear as early 
as 4 weeks which leads to an early death. They show an increase of vascular permeability, 
loss of pericytes, loss of BRB function and a decrease of retinal layer thickness, 
characteristics of RD development. 
[64]
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2. Objective 
It has been previously described that glucose is exclusively transported into the retina 
by GLUT1 and hyperglycemia present in DR causes an increase of this transporter in the 
retina. It is also known that HIF-1 plays an important role under hypoxic conditions by 
acting as a transcription factor of several genes, such as GLUT-1 and VEGF. It has also 
been described that there is an imbalance between angiogenic and anti-angiogenic factors 
like VEGF and PEDF in DR. Our working hypothesis is that the increase of GLUT1 and 
the imbalance between VEGF and PEDF are the main cause of DR development. 
Therefore, using DR models, the general aim of this work was to characterize the 
expression of GLUT1, VEGF and PEDF and it was divided in two parts: 
2.1. Characterization of pro- and anti-angiogenic factors in in vitro models. 
2.2. Characterization of pro- and anti-angiogenic factors in in vivo models. 
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3. Materials and Methods 
3.1 MTT assay 
Cells were seeded at a density of 5.0 × 10
4
 cells/ well in 24-well flat-bottom tissue 
culture plates and were maintained for 72h in culture medium containing 5 mM of D-
Glucose, 25 mM of D-Glucose or 25 mM of mannitol. DFO was added 16h prior the MTT 
assay in order to induce hypoxia. At 72 h, 50 μL of MTT (5 mg/mL, Sigma-Aldrich) were 
added to each well and incubated for 4 hours, at 37 ºC. To dissolve the formed formazan 
crystals, the medium was replaced with 500 μL of 0.04N HCl/ Isopropanol. Absorbance 
was measured using a micro-plate reader (Tecan Infinite 2000, USA), at 570 nm (for 
cell viability/formazan formation) and 630 nm (background/cell debris). After subtracting 
the background (optical density (OD) = OD570 nm – OD630 nm), cell viability was 
calculated as follows: Cell viability (%) = (OD sample)/ (OD control) × 100. Cells 
incubated with a latex extract in culture medium were used as control for cell death. 
  
3.2 Cell culture and Treatment 
The in vitro studies were performed in the human RPE cell line, D407. This cell line 
was derived from the eyeball of a 12 year-old child 
[61]
 and  have been extensively used as 
a model of the RPE. 
[61]
 D407 cells were maintained in humidified atmosphere with 5% 
CO2 at 37ºC in high-glucose Dulbecco’s Modified Eagle's Medium (DMEM, Sigma) 
containing 10% Fetal Bovine Serum (FBS), 1% penicillin/streptomycin (Sigma) and 1% L- 
Glutamin (Sigma). 
D407 cells were exposed to two oxygen tension conditions, normoxia or hypoxia, and 
treated with 2 concentrations of glucose, 5.5mM (corresponding to a normoglycemic 
condition) or 25mM (corresponding to a hyperglycemic condition) (Table 3.1). 
[65]
 As a 
control, the cells were also treated with DMEM containing mannitol, at a final 
concentration of 25mM. 
Mannitol is a sugar alcohol that can be used as an osmotic control substance and a 
glucose metabolism control because does not influence significantly the blood sugar levels. 
[66]
 
[67]
 
Normoxia condition represents retina under normal circumstances, which worked as a 
control, and hypoxia condition represents retina under pathological conditions like in DR. 
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Table 3.1: The conditions tested in vitro models. 
 
 
 
 
For induction of hypoxia, it was used desferrioxamine (DFO, Sigma) at a final 
concentration of 100 µM, previously described in other study. 
[68]
 
DFO is an iron chelating agent often used as a hypoxia-mimetic agent to stabilize HIF-
1α. [69] Under normoxic conditions and in the presence of iron, HIF-1α is hidroxylated by 
prolyl hydroxylases (PHDs) and subsequently degraded by the proteasome. On the other 
hand, under hypoxia or in the presence of DFO, due to the chelation of iron (which is 
required for enzymatic activity of PHD), HIF-1α is stabilized and dimerizes with its β-
subunit, originating a functional complex (fig. 3.1). 
[70]
 
[69] 
 
 
 
 
 
 
 
Figure 3.1: Inhibition of the HIF hydroxylation by DFO. Adapted from 
[71]
. 
 
3.3 Animals 
C57BL/6J Ins2
Akita
 heterozygote male mice (Jackson Laboratory, Bar Harbor, ME) 
were used as a DR model. The females were not used in this study because the disease 
progression is slower and less uniform. 
[64]
  
C57BL/6J age-matched (WT; Jackson Laboratory, Bar Harbor, ME) mice were used as 
a control group. 
Mice were housed in plastic cages in a pathogen-free environment, with continuous 
access to food and water on a 12 hour light/ dark schedule. 
The diabetic phenotype was confirmed 2 months after birth by blood glucose > 250 
mg/dL (One Touch UltraEasy, Lifescan) in a drop of blood from a tail’s cut.  
Normoxia Hipoxia 
DMEM 5mM D-Glucose DMEM 5mM D-Glucose 
DMEM 25mM D-Glucose DMEM 25mM D-Glucose 
DMEM 25 mM mannitol DMEM 25 mM mannitol 
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C57BL/6J Ins2
Akita
 heterozygote mice and WT mice were sacrificed at the age of 6 and 
12 months, that corresponds to the onset and chronic stage of the disease . 
 
3.4 RT-PCR and qRT-PCR 
RNA Extraction and Reverse Transcription 
Total RNA from cell samples were extracted using the RNA extraction kit “Quick-
RNA™ MiniPrep” (Zymo Research) according to the manufacter’s instructions.   
Total RNA from neural retina were extracted using “RNeasy mini kit” (Qiagen) 
according to the manufacter’s instructions.  
After spectrophotometric quantification of RNA using NanoDrop 2000c (Thermo 
scientific), reverse transcription was carried out using “The High Capacity cDNA Reverse 
Transcription Kits” (Applied Biosystems) according to the manufacter’s instructions.  
Polymerase chain reaction (PCR) 
cDNA amplification was performed by using 1µg of RNA as template, PEDF, VEGF, 
GLUT1 or β-ACTIN specific primers (10μM; see Appendix 1), dNTPs, cDNA, taq 
(Invitrogen), taq buffer, MgCl2 (50mM) and sterile water. The amplification parameters set 
for PEDF and VEGF were 95ºC for 5 min, 95ºC for 30 s, 55ºC for 30 s, 72ºC for 1 min 
(total 35 cycles) and for GLUT1 and β-ACTIN were 95ºC for 5 min, 95ºC for 30 s, 62ºC 
for 30 s, 72ºC for 1 min (total 35 cycles). 
The amplification products were loaded in a 2% electrophoresis gel and stained with 
GreenSafe Premium (NzyTech). 
Real Time PCR (qRT-PCR) 
Specific primers for PEDF, VEGF, GLUT1 or β-ACTIN (5µM) were used for qRT-
PCR (Appendix 1). The qPCR was performed using SsoFast EvaGreen Supermix (Bio-
Rad) according to the manufacter’s instructions. 
The average CT (threshold cycle) of fluorescence units was used to analyze the mRNA 
levels. PEDF, VEGF and GLUT1 mRNA levels were normalized by β-ACTIN RNA 
levels. Quantification was calculated as: mRNA levels (percent of control) = 2 ∆
(CT)
 with 
∆(CT) = CT (PEDF, VEGF, GLUT1)- CT β-Actin. 
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3.5 Western Blot analysis 
Primary Antibodies: Anti-PEDF antibody ab180711 (rabbit, Abcam); Anti-VEGF 
antibody ab46154 (rabbit, Abcam); Anti-Glucose Transporter GLUT1 antibody ab32551 
(rabbit, Abcam). Dilutions described in table 3.2. 
Secondary Antibodies: Goat anti-mouse IgG-HRP: sc-2005 (Santa Cruz 
Biotechnology); goat anti-rabbit IgG-HRP: sc-2004 (Santa Cruz Biotechnology). 
Table 3.2: Antibodies dilutions for Western Blot. 
Western Blot 
 1ºAntibody dilution Time 2º Antibody Dilution Time 
GLUT1 1:3000 ON/4ºC 1:5000 1h/RT 
VEGF 1:1000 ON/4ºC 1:5000 1h/RT 
PEDF 1:1000 ON/4ºC 1:10000 1h/RT 
β-Actin 1:10000 1h/RT 1:5000 1h/RT 
 
Protein Extraction 
For protein extraction from cells culture samples, the D407 cells were plated in 60 mm 
dishes until reach 90% of confluence. The whole extract proteins were collected in cold 
RIPA buffer (50 mM Tris-HCl pH 7.4, 0.25% Na-deoxycholate, 1% NP-40, 150 mM 
NaCl, 1mM EDTA) containing protease inhibitor cocktails. 
The lysate was cleared by centrifugation at 13200 rpm for 20 min at 4ºC and the 
supernatant stored at – 20ºC, for further quantification using the Bradford assay.  
Eyes from animals of 6 and 12 month-old were dissected after cervical dislocation. For 
neural retina isolation, the anterior chamber, containing the cornea, lens, vitreous and 
aqueous humor was removed, and the retina was peeled from RPE. Retinas and RPE were 
dissected, homogenized in 100µl of cold RIPA buffer and incubated at 4ºC for 20 min. 
Homogenates were cleared by centrifugation at 13200 rpm for 20 minutes at 4ºC and 
stored at -80ºC. The protein concentration was determined using the Bradford assay. 
Western blot 
A total of 30 µg of protein were resolved by 12% SDS-PAGE gel, transferred to a 
PVDF membrane (GE HealthCare)  and blocked in Superblock Blocking solution (Thermo 
Scientific), containing 0.1% of Tween-20 for 1h at RT. Then, the membrane was incubated 
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ON, at 4ºC with the primary antibody diluted in Superblock Blocking solution containing 
0,1% Tween 20.  
The membrane was washed with Tris-Buffer Saline (20 mM Tris base, 150 mM NaCl 
pH 7,6) with 0,1% tween 20 (TBS.T; 3 x 10 min), and  was probed with an HRP-
conjugated secondary antibody for 1h at RT diluted in Superblock Blocking solution 0,1% 
Tween 20. 
As a loading control, we used β-Actin. For β-Actin detection, the membrane was 
blocked for 1h at RT with Superblock Blocking solution 0,1% Tween 20 and incubated for 
1h at RT with β-Actin antibody diluted in Superblock Blocking solution 0,1% Tween 20.  
After it was washed with TBS.T (3 x 10 min), it was probed with HRP-conjugated 
secondary antibody diluted in Superblock Blocking solution 0,1% tween for 1h at RT. 
Immunoreactive bands from the membrane were detected through ChemiDoc MP 
System (Bio-Rad) by its chemiluminescence, using an ECL plus kit (GE Healthcare).  
 
3.6 Immunocytochemistry and Immunohistochemistry 
Primary Antibodies: Anti-PEDF antibody Sc-25594 (rabbit, Santa Cruz); Anti-VEGF 
antibody ab46154 (rabbit, Abcam); Anti-Glucose Transporter GLUT1 antibody ab32551 
(rabbit, Abcam). Dilutions are in table 3.3 and 3.4. 
Secondary antibodies: Alexa fluor Goat anti-rabbit 594 (Molecular Probes). 
Immunocytochemical Staining of PEDF, VEGF and GLUT1 
Table 3.3: Antibodies dilutions for Immunocytochemistry. 
D407 cells were seeded at a concentration of 7 x 10
4
 cell/well and grown on sterile 
glass coverslips in 12-well plates with culture media containing different concentrations of 
D-Glucose, for 3 days. To mimic hypoxic conditions, the cells were then incubated with 
DFO at concentration of 100 μM, for 16h and fixed for 10 min in ice-cold methanol, for 10 
Immunocytochemistry 
 1ª Antibody dilution Incubation 
Time 
2º Antibody dilution Incubation 
Time 
GLUT1 1:250 1h/RT 1:500 1h/RT 
VEGF 1:100 1h/RT 1:500 1h/RT 
PEDF 1:100 1h/RT 1:500 1h/RT 
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minutes. Methanol is an organic solvent that preserve the cells by removing its lipids, then 
dehydrate them and precipitate the proteins present in the cells. 
[72]
 
Following fixation, the cells were washed in 0,2% Triton X-100 in Phosphate-buffered 
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7,4) (3 
x 5 min) and incubated with a blocking solution (1% goat serum in PBS 0,2% Triton X-
100) for 30 min, at room temperature (RT) before incubating with the primary antibody 
diluted in PBS 0.2% Triton X-100 for 1h at RT. 
After 3 washes with PBS-T, the coverslips were incubated with the secondary 
antibody, for 1h at RT, protected from light. The cells were then washed in PBS 0,2% 
Triton X-100 (3 x 5 min) and mounted with Fluoromount G (Electron Microscopy 
Sciences) containing  DAPI, for following light microscopy analysis. 
 Images were obtained using an AxioVision microscope with a 63× objective, using the 
appropriate filter sets (Axio Observer Z2, Zeiss). 
Immunohistochemical staining of PEDF, VEGF and GLUT1 in the mouse retinas  
Table 3.4: Antibodies dilutions for Immunohistochemistry. 
The eyes were enucleated and immediately fixed in ice-cold 4% paraformaldehyde 
(PFA) in PBS, for 16 hours, cryoprotected in 30% sucrose (Sigma) in PBS and embedded 
in optimal cutting temperature (OCT; VWR) mounting medium, for cryosection. 10 µm 
thick serial sections were performed, placed on glass slides and stored at -20ºC. After 
drying for 1h30, the frozen sections were permeabilized with PBS 0.2% Triton X-100 for 
10 min.  
The retina is rich in endogenous fluorescence components such as melanin, lipofuscin 
and carotenoids which difficult the visualization of normal fluorescence. 
[73]
 To reduce the 
autofluorescence of the retina, the slices were incubated with 0.25% of potassium 
permanganate (KMnO4) in PBS for 15 min at RT, followed by a wash step with PBS 0.2% 
Immunohistochemistry 
 1ª Antibody dilution Incubation 
Time 
2º Antibody dilution Incubation 
Time 
GLUT1 1:250 ON/4ºC 1:500 1h/RT 
VEGF 1:100 ON/4ºC 1:500 1h/RT 
PEDF 1:100 ON/4ºC 1:500 1h/RT 
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Triton X-100 (2 x 5 min) and treated with 5% of oxalic acid (H₂C₂O₄) in PBS. Both 
KMnO4 and H₂C₂O₄ have been described as bleachers to the retina autofluorescence. 
[74]
  
After reducing the autofluorescence, the sections were washed with PBS 0.2% Triton 
X-100 (3 x 10 min), blocked  with 1% of goat serum in PBS 0.2% Triton X-100 for 1h at 
RT, followed by incubation with  the primary antibody diluted in PBS 0.2% Triton X100.  
After an ON incubation at 4ºC, , the cells were washed with PBS 0.2% Triton X-100 (4 
x 10 min) and then incubated with the secondary antibody diluted in PBS 0.2% Triton X-
100 for 1h at RT, in a humid chamber protected from light. 
The samples were then washed with PBS 0.2% Triton X-100 (4 x 10 min), mounted on 
glass slides with Fluoromount G containing DAPI and the images were obtained using an 
AxioVision microscope with a 40× objective, using the appropriate filter sets (Axio 
Observer Z2, Zeiss). 
 
3.7 Cellular protein membrane extraction 
Cells were grown on 100 mm dishes to reach confluence and were washed with ice-
cold PBS (2x). The cells were homogenized in 1 ml of homogenization buffer (20 mM 
HEPES  pH 7.4; 1mM); EDTA; 250 mM Sucrose; 1x protease inhibitors cocktail).  
Homogenates were cleared by centrifugation at 3500 rpm for 10 minutes at 4ºC and the 
supernatant transferred to a fresh centrifuge tube. The lysate was then centrifuged at 100 
000 g for 1h at 4ºC. 
The resulting supernatant, corresponding to the cytosolic fraction, and the pellet, 
corresponding to the membrane fraction, was resuspended in a resuspension buffer (10 
mM HEPES pH 7.4; 250 mM Sucrose; 1x protease inhibitor cocktail). 
The protein concentration was determined using the Bradford assay. 
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4. Results and Discussion 
As previously reported, DR is a microvascular complication associated with DM and 
the leading cause of blindness in developed countries. 
[75]
 Some studies have shown that 
mechanisms involving hyperglycemia and hypoxia are key factors in the onset, progression 
and prognosis of the disease. 
[42]
 
[76]
 The increase of glucose by GLUT1 activates several 
biochemical pathways that culminate with DR appearance. 
[14]
 It was also described that in 
patients suffering DR there is an imbalance between pro- and anti-angiogenic molecules, 
such as VEGF and PEDF, respectively, that are also responsible for the onset of the 
disease. 
[59]
 
[60]
 
So, with this study, we intended to evaluate the expression of GLUT1, VEGF and 
PEDF in DR models under DR conditions. 
4.1 Characterization of pro- and anti-angiogenic factors in in vitro models 
To evaluate the expression of pro- and anti-angiogenic factors we developed an in vitro 
system DR, using human RPE cells. D407 cells were cultured either with 5 mM of D-
Glucose (corresponding to normoglycemia) or 25 mM of D-Glucose (simulating 
hyperglycemia). In addition, cells were subjected to hypoxia by the addition of DFO, a 
chelating agent that induces hypoxia by inhibiting HIF-1α degradation at the proteasome.  
Figure 4.1: Effect of glucose and DFO upon cellular viability of RPE cells. Cellular 
viability, measured by MTT assay, of D407 RPE cells in the presence of different 
concentrations of glucose (5.5 mM and 25 mM of D-Glucose) and mannitol upon exposure 
to DFO during 16h. Latex extract was used as the negative control for viability. *P<0.05 
indicates that latex extract values are significantly different from glucose values 
determined by Sidak’s multiple comparisons test. 
 
To exclude possible toxicity induced by the addition of DFO to the cells, we decided to 
perform an MTT assay. The MTT assay is a colorimetric assay that assesses the 
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cytotoxicity and the cell viability under defined conditions in which viable cells convert 
MTT into a purple colored formazan product which it is measurable. 
[77]
 Our results 
demonstrate that DFO does not induce significant cell death in all the concentrations tested 
(fig. 4.1).  
 
4.1.1 Characterization of GLUT1 in D407 cells 
In order to assess how glucose concentration and hypoxia influences GLUT1 
expression, we decided to analyze GLUT1 mRNA levels by real-time qPCR (fig. 4.2). Our 
results show that hypoxia induces an increase (fig. 4.2A) of 20-fold in GLUT1 mRNA (fig. 
4.2B). According to literature, the increase detected in hypoxia is expected due to the HIF-
1 cascade activation. 
[78]
 Moreover we found no significant differences in GLUT1 mRNA 
levels among the various glucose concentrations in which the cells were cultured (Fig. 4.2). 
This result is also in line with literature that state that there is no significant change in the 
levels of GLUT1 mRNA between cells incubated in medium with low and high glucose.
 
[50]  
Figure 4.2: GLUT1 mRNA expression in RPE cells cultured under diabetic environment. 
PCR (A) and qPCR (B) analysis of GLUT1 in D407 cells cultured under normoxia (N) and 
hypoxia (H) conditions and different concentrations of glucose in the culture medium: 5 
mM of D-Glucose (corresponding to normoglycemia), 25 mM of D-Glucose (simulating 
hyperglycemia) and 25 mM of Mannitol (osmolarity control). N=3, *P<0.05 indicates 
significant differences in the mRNA levels of GLUT1 in hypoxia compared with the cells 
cultured in normoxia, determined by Tukey’s multiple comparisons test. 
We also evaluated GLUT1 expression at the protein level. We found a marked increase 
in GLUT1 protein expression induced by hypoxia in the cells cultured under diabetic 
conditions (fig. 4.3).  However, figure 4.3 shows no difference, at the protein level, in the 
normoglycemic conditions, in normoxia compared with hypoxia. This means that despite 
the increase of GLUT1 mRNA levels due to hypoxia (fig. 4.2B), there is no translation into 
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protein. One hypothesis to explain this result is the translation machinery is diminished in 
hypoxic conditions which may affect the translation of GLUT1. 
[79]
 On the other hand, we 
verify an increase of about 1.5 times in GLUT1 protein (fig. 4.3B) in the cells cultured 
with 25 mM of D-Glucose subjected to hypoxia when compared with the cells cultured 
with the same glucose concentration under normoxia conditions, showing a positive effect 
of glucose concentration in the translation of GLUT1 mRNA into protein. These results are 
complementary with the previous results and support by the literature. 
[80]
 
Figure 4.3: Effects of glucose and hypoxia in GLUT1 protein expression. (A) corresponds 
to Western Blot analysis of GLUT1 in the different treatments performed and (B) 
represents the quantitative data normalized by the intensity of β-ACTIN bands. N=4, 
*P<0.05 represents significant difference and ns indicates no significant difference in 
GLUT1 protein level in the cells cultured under hypoxia with high glucose concentration 
medium, determined by Tukey’s multiple comparisons test. 
 
In order to better understand the mechanism underlying GLUT1 overexpression in the 
cells cultured in a diabetic condition, we performed an immunocytochemistry to trace 
GLUT1 in human RPE cells (fig. 4.4). There is a clear overexpression of GLUT1 in the 
membrane of the hypoxic cells compared with the normoxic cells (fig. 4.4). These results 
are in accordance with the previous hypothesis and the literature which says that in cells 
and tissues such as cardiac and skeletal muscle there is a major translocation of Glut4 and 
Glut1 induced by hypoxia. 
[81]
  
Also, it is possible to observe in figure 4.4 that GLUT1 staining was stronger in the 
hypoxic cells cultured under a hyperglycemic condition compared with the cells cultured 
under a normoglycemic condition which is in accordance with the previous results from 
Western blot. 
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Figure 4.4: Immunocytochemistry staining of GLUT1 (red) in human RPE cells. D407 
cells were cultured with different concentrations of glucose and were subjected to hypoxia 
and normoxia conditions. DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 
20 µM.  
To prove our previous results we decided to isolate cytosolic and membrane proteins 
and we evaluated GLUT1 expression in both fractions by Western blot (fig. 4.5). As we 
can see illustrated in figure 4.5, there is a marked increase of GLUT1 expression in the 
membrane fraction of the hypoxic cells compared with the normoxic cells which is in 
accordance with the hypothesis that there is translocation of the GLUT1 to the membrane 
in response to hypoxia (fig. 4.5). 
 
 
 
 
 
Figure 4.5: GLUT1 stabilization in the cell membrane in response to hypoxia. Western 
Blot analysis of GLUT1 in the cytosolic and membrane fraction of D407 cells cultured 
with 25 mM of D-Glucose, subjected to normoxia (N) and hypoxia (H).  
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Moreover, we could not observe a significant increase of GLUT1 in the cytosolic 
fraction of the hypoxic cells,  supporting the idea that the increase that the overall increase 
in GLUT1 that we observed in the Western blot analysis is due to an increase of GLUT1 
expression in the those cells. This increase can be due to the fact that hypoxic cells need to 
increase glucose uptake due to enhanced anaerobic glycolytic pathway. 
[82]
 
 
4.1.2 Characterization of PEDF in D407 cells 
After the evaluation the GLUT1 expression, we decided to assess the PEDF expression 
in hypoxic conditions and cultured underlow glucose and high glucose concentrations. 
First, we decided to analyze the mRNA levels of PEDF by real time qPCR. Despite our 
efforts and after changing several times the primers used for this experiment (appendix 1), 
we were not able to access PEDF mRNA expression due to unspecific amplification of the 
negative control. Due to this, we decided to move on and evaluate the protein level of 
PEDF by Western blot on those conditions (fig. 4.6).  
Figure 4.6: Effects of glucose and hypoxia in PEDF protein expression. (A)  Corresponds 
to Western Blot analysis of PEDF in the different treatments performed and (B) represents 
the quantitative data normalized by the intensity of β-Actin bands. N=4, ns represents no 
significant difference (P>0.05) in PEDF protein level in the cells cultured under hypoxia 
with high glucose concentration medium, determined by Tukey’s multiple comparisons 
test. 
As we can see represented in figure 4.6B there is no significant difference between 
hypoxic and normoxic conditions in the cells cultured under normoglycemia and 
hyperglycemia conditions. Nevertheless we can see in figure 4.6 (A and B) there is a slight 
tendency for decrease in PEDF expression in the cells cultured under hypoxia conditions 
when compared with the cells cultured under normoxia conditions. This result is in 
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accordance with the literature. [83] The slight decrease of the PEDF expression may be 
explained by the fact that this factor is produced and secreted by RPE cells. This can be the 
reason why we cannot detect a significant decrease in the intracellular protein. [84] Since 
PEDF is a secreted protein, it would be interesting to evaluate the protein levels in the 
supernatant of the cells and verify if its expression is altered. 
Subsequently, we evaluate the expression levels of PEDF in D407 cells by 
immunocytochemistry (fig. 4.7).  
Figure 4.7: Immunocytochemistry staining of PEDF (red) in human RPE cells. D407 cells 
were cultured with different concentrations of glucose and were subjected to hypoxia and 
normoxia conditions. DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 20 
µM. 
 
As we can see in figure 4.7 there is a slight decrease in PEDF expression in the cells 
cultured under hypoxic condition. This result is in accordance to our Western blot results 
in which we found a tendency to decrease in PEDF protein.   
 
4.1.3 Characterization of VEGF in D407 cells 
Knowing that VEGF expression levels are imbalanced in DR, we also decided to 
evaluate the VEGF expression in hypoxic conditions and under normoglycemia and 
hyperglycemia conditions. To start, we analyzed the mRNA expression levels of VEGF by 
real time qPCR (fig. 4.8). 
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In our PCR (fig. 4.8A) result it seems that there is a slight increase between normoxia 
and hypoxia. This result was confirmed by qPCR analysis (fig. 4.8B) which shows that 
hypoxia induces a significant increase (of about 3 times) in VEGF mRNA than in 
normoxia. These results are in accordance with the literature which says that HIF-1α, that 
it is stabilized in hypoxia, induces VEGF expression. 
[56]
  
Figure 4.8: VEGF mRNA expression in RPE cells cultured under diabetic environment. 
PCR (A) and qPCR (B) analysis of VEGF in D407 cells cultured under normoxia (N) and 
hypoxia (H) conditions and different concentrations of glucose in the culture medium: 5 
mM of D-Glucose, 25 mM of D-Glucose and 25 mM of Mannitol. N=3, *P<0.05 indicates 
significant differences and ns indicates non-significant differences in the mRNA levels of 
VEGF in hypoxia compared with the cells cultured in normoxia, determined by Tukey’s 
multiple comparisons test. 
However, when we compared different glucose concentrations under normoxia 
conditions, we can see that there is a slight decrease of the VEGF mRNA expression in 
hyperglycemia (fig. 4.8B). This result was opposite to what we were expecting. We were 
expecting to have a stronger increase in VEGF mRNA expression in the cells cultured with 
high glucose medium. One hypothesis to explain this result is the fact that the VEGF is a 
factor that regulates glucose passage across blood barriers so, before the typical increase of 
VEGF mRNA expression, maybe there is a decrease as a defense mechanism of the cell to 
prevent more glucose entrance. 
[85]
 In addiction, other study demonstrates  that 
hyperglycemia has been shown to reduce the levels of VEGF RNA whose our results 
seems to be in accordance.
[86]
 So, we can say that hypoxia maybe is the main promoter of 
the VEGF mRNA increased expression. 
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Figure 4.9: Effects of glucose and hypoxia in VEGF protein expression. (A) Corresponds 
to Western Blot analysis of VEGF in the different treatments and (B) represents the 
quantitative data normalized by the intensity of β-Actin bands; N=4 ,ns indicates no 
significant difference in VEGF protein level in the cells cultured under hypoxia with high 
glucose concentration medium, determined by Tukey’s multiple comparisons test. 
Next, we decided to analyze the protein expression of VEGF (fig. 4.9). In figure 4.9A 
we can see that in normoglycemia there is a slight increase of VEGF protein comparing 
normoxia with hypoxia which is in accordance with the qPCR results and the literature 
(Fig. 4.9B). 
[87]
 Similarly, despite the slight decrease at mRNA level, there is a significant 
increased at protein level in the cells cultured with high glucose medium compared with 
the cells cultured with normoglycemic medium. This result suggests that the 
hyperglycemia effect on VEGF expression is induced at translational level. 
[88]
 However, 
when we evaluated the protein expression in high glucose condition, we can see that there 
is not a significant difference between normoxia and hypoxia conditions. This result is not 
in accordance with the literature that shows an increase in VEGF expression levels due to 
hyperglycemia and hypoxia. One possible explanation is the counteraction of PEDF in 
mRNA translation into protein. As we described earlier, PEDF expression levels are not 
changed in the presence of hypoxia and hyperglycemia, so we hypothesized that PEDF 
may lead to the blockage of VEGF production, as it was previously described by Takenaka 
et al. 
[89]
 Moreover, similarly to PEDF, VEGF is also a secreted protein and in critical 
conditions such as hypoxia, the produced protein is secreted to the supernatant decreasing 
the intracellular content of VEGF, explaining the slight decrease we observed. 
[90]
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In order to confirm the previous results, we also performed an immunocytochemistry to 
trace VEGF in human RPE cells (fig. 4.10). However, our results seem to show that there 
is no significant alteration in the expression of VEGF which is partially in accordance with 
the Western blot analysis (fig. 4.9).    
Figure 4.10: Immunocytochemistry staining of VEGF (red) in human RPE cells. D407 
cells were cultured with different concentrations of glucose and were subjected to hypoxia 
and normoxia conditions. DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 
20 µM.  
 
4.2 Characterization of pro- and anti-angiogenic factors in in vivo models 
To better understand the role of these factors in DR, we evaluated their expression in 
vivo. In this study we used retina and RPE samples of C57BL/6 WT and Ins2Akita mice 
with 6 and 12 months of age. 
Previous studies in Ins2Akita mice indicated that clinical symptoms of DR start at 6 
month of age, which represents the initial phase of the disease. [91] [92] Other study also 
showed that at 9 months of age the Ins2Akita start to develop PDR. [92] Therefore, the 
evaluation of angiogenic factors in mice with 12 months already represents severe state of 
the disease.   
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4.2.1 Characterization of GLUT1 in mouse models 
 Similarly to what was performed for the in vitro models, we started by analyzing  
GLUT1 mRNA expression levels by real time qPCR in retinas of 6 and 12 month-old mice 
(fig. 4.11). 
Figure 4.11: qPCR analysis of GLUT1 in C57BL/6 WT and Ins2
Akita
 with 6 (A) and 12 
months (B) of age. N=6; non-significant (ns) indicates no significant differences in the 
mRNA levels of GLUT1 in WT compared and Ins2
Akita, determined by Tukey’s multiple 
comparisons test.  
 In figure 4.11, in contrast to what we expected, there is no significant difference in 
GLUT1 expression in the WT retinas, when compared with the retinas of Ins2
Akita
 mice, for 
both the samples of animals with 6 and 12 months-old (fig. 4.11B). This can be due to the 
fact that at 6 months of age mice are at the onset of the disease, which may not yet affect 
the mRNA expression of GLUT1. 
[91]
 Likewise, we found no significant differences in the 
GLUT1 mRNA expression levels at 12 months of age. This can be related with the severe 
state of the disease where the retina is senescent. 
[93]
 
The expression of GLUT1 was also evaluated by Western blot and as we can see in 
figure 4.12, there is a significant increase of GLUT1 protein in the retina of 6 month-old 
Ins2
Akita
 when compared with the WT animals.  
This increase is in accordance to what we were expecting and may indicate that the 
mice are at the beginning of the disease when hyperglycemia is already installed and, 
consequently, there is an overexpression of GLUT1 protein. However this is not in 
agreement with our qPCR results in which we see no increase in the mRNA expression of 
GLUT1 in the retinas of the diabetic mice, when compared with WT (non-diabetic). This 
could be due to the fact that the mice may be in the early phase of the disease where the 
increase of the expression may be mediated at translational level leading to a difference at 
the protein level but not at the mRNA level. 
[81]
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Figure 4.12: GLUT1 expression in C57BL/6 WT and Ins2
Akita
 with 6 months of age in the 
retina. (A) corresponds to Western blot analysis of GLUT1 expression levels and (B) 
corresponds to the quantitative data normalized by the intensity of β-Actin bands. N=4; 
*P<0.05 represents significant difference in glut1 protein level GLUT1 between C57BL/6 
WT and Ins2
Akita, determined by Tukey’s multiple comparisons test. 
 
 Nevertheless, there is no significant difference in the expression of GLUT1 at 12 
months of age in both strains (fig. 4.13A and 4.13B). This result is in accordance with the 
mRNA levels at this age which may also be associated with the presence of a severe state 
of the disease that is installed at that age. 
[93]
 However, it seems that GLUT1 protein has 
tendency to be higher in Ins2
Akita
 than in WT. This result is in accordance with the 
literature that says that in the presence of chronic hyperglycemia there is an increase of 
Glut1 expression. 
[14]
 
Figure 4.13: GLUT1 expression in C57BL/6 WT and Ins2
Akita
 with 12 months of age in 
the retina. (A) corresponds to Western blot analysis of GLUT1 expression levels and (B) 
corresponds to the quantitative data normalized by the intensity of β-Actin bands. N=3; ns 
indicates no significant differences in the protein expression of GLUT1 in WT compared 
with Ins2Akita, which was determined by Tukey’s multiple comparisons test. 
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Figure 4.14 represents an immunohistochemistry of Glut1 in the retina of animals with 
6 months. Interestingly there is a marked increase in Glut1 staining in the membrane of the 
retinal cells of Ins2Akita mice. This result is in accordance with our previous results in D407 
cells (fig. 4.5) that shows a predominant expression in the cellular membranes. 
Figure 4.14: Immunohistochemistry staining of GLUT1 in retina sections of C57BL/6 WT 
(A) and Ins2Akita (B) with 6 months of age. GCL - Ganglionar cell layer; IPL- inner 
plexiform layer; INL – Inner nuclear layer; OPL – outer plexiform layer; ONL – outer 
nuclear layer; RCL – Rod and cones layer. Red staining corresponds to GLUT1expression 
and DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 20 µM. 
Figure 4.15: Immunohistochemistry staining of GLUT1 in retina sections of C57BL/6 WT 
(A) and Ins2Akita (B) with 12 months of age. GCL - Ganglionar cell layer; IPL- inner 
plexiform layer; INL – Inner nuclear layer; OPL – outer plexiform layer; ONL – outer 
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nuclear layer; RCL – Rod and cones layer. Red staining corresponds to Glut1expression 
and DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 10 and 20 µM. 
 
For the immunohistochemistry of Glut1 transporter at 12 months of age, there seems to 
be an increase of intensity in the expression of GLUT1 in Ins
2Akita 
comparing with WT (fig. 
4.15). This result is in accordance to what it was expected, since from the literature in the 
presence of chronic hyperglycemia there is an increase of this transporter. 
[14] 
Also, this 
result confirms the tendency of GLUT1 expression to be higher in Ins2
Akita
 that we 
described earlier, which possibly would be significant if we had increased the sample 
number. However, we did not see the same marked increase of this transporter localized in 
the membranes that we saw at 6 months of age. Instead, the expression was spread 
throughout the entire cell. This may indicate that GLUT1 was not being translocated to the 
membranes and if cytosolic GLUT1 is elevated, the mRNA production may not vary, 
which explains the unchanged mRNA expression at 12 months of age. 
Summarizing, the GLUT1 expression in Ins2
Akita
 start to increase by the presence of  
hyperglycemia but in the early phase of the disease this increase is mainly at the 
translational level leading to an increase of GLUT1 in the membrane of the retinal cells. 
With the progression of the disease we can see that this increase is maintained.  
 
4.2.2 Characterization of PEDF in mouse models 
After analyzing GLUT1 expression, we decided to analyze the expression levels of 
PEDF. We started to analyze the expression of PEDF mRNA levels by real-time qPCR 
(fig. 4.16). Our result shows that there is not a significant difference in the expression of 
PEDF mRNA between WT and Ins2
Akita 
in both time-points that we analyzed. It is known 
that the mice start developing some features of DR at 6 months of age, meaning that they 
are at the beginning of the disease which may not yet influence the PEDF mRNA 
production. However as we can see in figure 4.16A there is a tendency to increase the 
PEDF mRNA expression in Ins2
Akita 
mice. Knowing that hyperglycemia elevates the levels 
of angiogenic factors, such as VEGF, and at 6 months of age the hyperglycemia is already 
installed, this increase of PEDF expression may be to counteract the increase of this 
angiogenic factors. 
[94]
 However, as we can see in figure 4.16B, that represents 12 months 
of age and the most severe state of the disease, there is no significant difference between 
both strains. One possible explanation to these unchanged levels could be the senescence 
that it is present in the retina at this age even for the WT mice.  
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Figure 4.16: qPCR analysis of PEDF in C57BL/6 WT and Ins2
Akita
 with 6 months (A) and 
12 months of age (B); N= 6; ns indicates no significant differences in the mRNA levels of 
PEDF in WT compared and Ins2
Akita, determined by Tukey’s multiple comparisons test. 
 
We decided to next analyze the protein levels of PEDF by Western Blot in the retina 
and RPE layer. We can see in figure 4.17 and 4.18 a decreased expression of PEDF both in 
the retina (fig. 4.17) and RPE layer (fig. 4.18) of the diabetic mice. Although the PEDF 
expression in the retina is not in accordance with the mRNA levels from figure 4.16, this  
was expected based on the literature, which shows that PEDF is decreased in cases of DR.
 
[59]
 So analyzing both mRNA and protein expression, we can say that mRNA levels have a 
tendency to increase because it is trying to compensate the decrease of PEDF protein 
expression. In addiction it seems that the decrease of PEDF expression is much more 
pronounced in the RPE layer than in the retina which is also expected because the RPE 
layer is one of the major production sources of PEDF (fig.4.18). 
[83]
  
 
Figure 4.17: Western Blot analysis of PEDF expression in C57BL/6 WT and Ins2
Akita
 with 
6 months of age in the retina. (A) corresponds to Western blot analysis of PEDF expression 
levels and (B) corresponds to the quantitative data normalized by the intensity of β-Actin 
bands. N=3; *P<0.05 indicates significant differences in the protein levels of PEDF in WT 
compared and Ins2
Akita, which was determined by Tukey’s multiple comparisons test.  
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Figure 4.18: Western Blot analysis of PEDF expression in C57BL/6 WT and Ins2
Akita 
with 
6 months of age in the RPE layer. (A) corresponds to Western blot analysis of PEDF 
expression levels and (B) corresponds to the quantitative data normalized by the intensity 
of β-ACTIN bands. N=3; *P<0.05 indicates significant differences in the protein levels of 
PEDF in WT compared and Ins2
Akita, which was determined by Tukey’s multiple 
comparisons test. 
 
Afterwards we analyzed the protein levels of PEDF in mice with 12 months old (fig. 
4.19 and 4.20). In the retina of 12 months old mice there is non-significant difference in 
the PEDF expression between WT and Ins2
Akita 
(fig. 4.19). This is in accordance with the 
mRNA levels at 12 months of age (fig. 4.16) which also show a non-significant increase of 
its expression. However we can see that Ins2
Akita
 mice have a tendency to increase the 
PEDF expression when compared with WT. This increase of PEDF protein maybe is an 
attempt to counteract the angiogenic factors that are described to be elevated at this stage.
 
[95]
 
When we evaluated the expression in the RPE layer, the protein expression of PEDF in 
Ins2
Akita
 with 12 months of age is completely abolished comparing with the PEDF 
expression in the RPE of WT mice (fig. 4.20). One possible explanation is that in 
conditions of chronic hypoxia there is a necessity of increasing the vascularity and 
angiogenesis. 
[96]
 To do so, it is necessary to increase angiogenic factors and subsequently 
decrease the anti-angiogenic factors. So the abolishment of PEDF proteins in the RPE of 
12 months Ins2
Akita
 mice may be derived from this decrease of the anti-angiogenic factors 
in response to chronic hypoxia. 
[97]  
However this result is not in accordance with the tendency of the PEDF expression to 
increase in the retina. This means that despite the abolition of PEDF in the RPE, PEDF 
levels in the retina in general are slightly increased. This increase maybe is associated with 
the production of PEDF by other retinal cells like Müller cells in which it was described by 
A B 
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β-ACTIN 
PEDF 
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Yang et al. that under hypoxia conditions, anti-angiogenic activity is secondary to the 
neuroprotective function inherent to PEDF. 
[98]
 Other possibility is that the RPE layer is 
dysfunctional at this age which may lead to the non-production and consequently the 
degradation of its principal factor. 
[99]
  
Figure 4.19: Western Blot analysis of PEDF expression in C57BL/6 WT and Ins2
Akita
 with 
12 months of age in the retina. (A) corresponds to Western blot analysis of PEDF 
expression levels and (B) corresponds to the quantitative data normalized by the intensity 
of β-ACTIN bands. N=3; *P<0.05 indicates significant differences and ns indicates non-
significant differences in the protein levels of PEDF in WT compared with Ins2
Akita
, which 
was determined by Tukey’s multiple comparisons test. 
Figure 4.20: Western Blot analysis of PEDF expression in C57BL/6 WT and Ins2
Akita
 with 
12 months of age in the RPE layer. (A) corresponds to Western blot analysis of PEDF 
expression levels and (B) corresponds to the quantitative data normalized by the intensity 
of β-ACTIN bands. N=3; *P<0.05 indicates significant differences and ns indicates non-
significant differences in the protein levels of PEDF in WT compared with Ins2
Akita
, which 
was determined by Tukey’s multiple comparisons test. 
 
Subsequently, we also performed an immunohistochemistry to evaluate PEDF 
expression in the retina and in the RPE layer. As we can see in figure 4.21, it seems to be a 
slight decrease of the PEDF expression in the Ins2
Akita
 at 6 months of age compare with 
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WT with the same age in the retina. This result is in accordance with our Western blot 
results (fig. 4.17) and with the literature. Likewise, we can see that there is a significant 
decrease of the Pedf expression in Ins2Akita mice compared with the 6 months-old WT mice  
in the RPE layer (fig. 4.22)  supporting our previous results. 
Figure 4.21: Immunocytochemistry staining of PEDF in retina sections of C57BL/6 WT 
(A) and Ins2Akita (B) with 6 months of age. GCL - Ganglionar cell layer; IPL- inner 
plexiform layer; INL – Inner nuclear layer; OPL – outer plexiform layer; ONL – outer 
nuclear layer; RCL – Rod and cones layer. Red staining corresponds to PEDF expression 
and DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 20 µM.  
Figure 4.22: Immunocytochemistry staining of PEDF in RPE sections of C57BL/6 WT 
(A) and Ins2Akita (B) with 6 months of age. ONL – outer nuclear layer; RCL – Rod and 
cones layer; RPE - retina pigmented epithelium. Red staining corresponds to PEDF 
expression and DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 20 µM. 
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Afterwards, through figure 4.23 we can see that there is no significant difference in the 
PEDF expression between Ins2Akita and WT at 12 months of age which also corroborates 
with the Western Blot analysis. We also tried to perform an immunohistochemistry against 
PEDF to stain the RPE layer of the animals with 12 months of age but the samples at this 
age were more damaged than usual. This can be due to RPE impairment along the 
progression of the disease. RPE composes the oBRB and is one of the first structures 
affected by the DR is the BRB. [99] [100] 
Figure 4.23: Immunocytochemistry staining of PEDF in retina sections of C57BL/6 WT 
(A) and Ins2Akita (B) with12 months of age. GCL - Ganglionar cell layer; IPL- inner 
plexiform layer; INL – Inner nuclear layer; OPL – outer plexiform layer; ONL – outer 
nuclear layer; RCL – Rod and cones layer. Red staining corresponds to PEDF expression 
and DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 20 µM. 
 
Summarizing, the PEDF expression levels in Ins2Akita mice at 6 months of age are 
decreased in both retina and RPE layer when compared with WT mice. In addition, this 
decrease is more pronounced in the latest. For mice with 12 months of age this decrease is 
only detectable in the RPE layer. 
 
4.2.3 Characterization of VEGF in mouse models 
Afterwards we decided to analyze the VEGF expression in WT and Ins2Akita mice with 
6 and 12 month-old. We first analyzed the VEGF mRNA expression by real-time qPCR. 
As we can see in figure 4.24A, at 6 months of age there is a significant increase of the 
VEGF mRNA expression in Ins2Akita compare with WT. This result is in accordance with 
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the literature that associated an increase of VEGF mRNA expression with the appearance 
of the disease.
[19]
 However, at 12 months of age despite it seems to have a tendency to an 
increase in VEGF expression, it is not significant (fig.4.24B). 
Figure 4.24: qPCR analysis of VEGF mRNA expression in C57BL/6 WT and Ins2
Akita
 
with 6 months of age (A) and 12 months of age (B). N=6; *P<0.05 indicates significant 
differences in the VEGF mRNA expression and ns indicates non-significant differences 
between WT and Ins2
Akita, which was determined by Tukey’s multiple comparisons test. 
 
Next, we analyzed the protein levels of VEGF in WT and Ins2
Akita
 mice with 6 months 
and 12 months of age by Western blot (fig. 4.25 and 4.26). Our results show that there are 
no significant differences between WT and Ins2
Akita
 mice at 6 months of age (fig. 4.25). 
This is not what we were expecting, taking into account the previous result from the qPCR 
and the literature. One hypothesis is that there might be degradation of the protein or other 
phenomenon that interferes with the translation of the mRNA. In fact, knowing that the 
translational machinery is diminished in hypoxic conditions, maybe the VEGF translation 
at the onset of the disease is also affected. 
[79]
 
Our result at 12 months of age shows that there is a significant decrease in VEGF 
protein expression (fig. 4.26) comparing WT with Ins2
Akita
 mice. This is the opposite of 
what we were expecting but this result can be explained by aging retinal cell death in the 
retina of the 12 month-old Ins2
Akita
 mice.
 [101]
 
[93] 
 
 
 
 
 
 
A B 
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Figure 4.25: Western Blot analysis of VEGF expression in C57BL/6 WT and Ins2
Akita 
with 
6 months of age in the retina. (A) corresponds to Western blot analysis of VEGF 
expression levels and (B) corresponds to the quantitative data normalized by the intensity 
of β-Actin bands. N=3; *P<0.05 indicates significant differences in the VEGF mRNA 
expression and ns indicates non-significant differences between WT and Ins2
Akita
, which 
was determined by Tukey’s multiple comparisons test.  
Figure 4.26: Western Blot analysis of VEGF expression in C57BL/6 WT and Ins2
Akita
 
with 12 months of age in the retina. (A) corresponds to Western blot analysis of VEGF 
expression levels and (B) corresponds to the quantitative data normalized by the intensity 
of β-Actin bands. N=3; *P<0.05 indicates significant differences in the VEGF mRNA 
expression and ns indicates non-significant differences between WT and Ins2
Akita
, which 
was determined by Tukey’s multiple comparisons test.  
 
Lastly, we also analyzed the VEGF expression in retinal samples by 
immunohistochemistry. As we can see in 6 month-old mice (fig. 4.27), it seems to be an 
increase of the VEGF expression in Ins2
Akita
 mice compared with WT. When we analyzed 
the expression of VEGF in mice with 12 months of age (fig. 4.28), it seems that there is no 
difference between WT and Ins2
Akita
. These results are not what we expected based on the 
Western blot results but the differences may be due to the fact that both 
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immunohistochemistry and Western blot are a qualitative method which may not detect the 
small differences between tested conditions.  
 
Figure 4.27: Immunocytochemistry staining of VEGF in retina sections of C57BL/6 WT 
(A) and Ins2Akita (B) with 6 months of age. GCL - Ganglionar cell layer; IPL- inner 
plexiform layer; INL – Inner nuclear layer; OPL – outer plexiform layer; ONL – outer 
nuclear layer; RCL – Rod and cones layer. Red staining corresponds to VEGF expression 
and DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 20 µM. 
Figure 4.28: Immunocytochemistry staining of VEGF in retina sections of C57BL/6 WT 
(A) and Ins2Akita (B) with 12 months of age. GCL - Ganglionar cell layer; IPL- inner 
plexiform layer; INL – Inner nuclear layer; OPL – outer plexiform layer; ONL – outer 
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nuclear layer; RCL – Rod and cones layer. Red staining corresponds to VEGF expression 
and DAPI (blue) represents the nuclei. Magnification: 63X, scale bar: 20 µM.  
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5. Conclusion 
RD is a microvascular complication associated to diabetes and the major cause of 
blindness among adults in developed countries. With the increase of T2DM, diabetic 
complications like RD are expected to rise, which makes it even more necessary to find a 
cure or a treatment for this pathology.  
The DR in vitro and in vivo models, like D407 cells and Ins2
Akita
 mice, respectively, are 
essential for the understanding of the biochemical mechanisms that leads to DR onset and 
progression. While D407 cells show a big similarity with the RPE cells that are present in 
the oBRB, the Ins2
Akita
 mouse is a spontaneous mouse model of T1DM that shows to be a 
suitable model for the study of diabetic complications like RD. 
The typical chronic hyperglycemia present in diabetic patients to which the retina is 
subjected leads to hypoxic conditions that activate a cascade of biochemical pathways that 
alter the levels of GLUT1 and pro and anti angiogenic factors such VEGF and PEDF. 
[16]
 
It is known that glucose transport from blood to retina is almost exclusively made by 
GLUT1, so alterations on its abundance and action may be associated with the DR 
symptoms. 
[14]
 Also, it is known that chronic hypoxia conditions lead to retinal 
neovascularization, 
[42]
 thus angiogenic factors are also associated with the development of 
DR pathology. The most important angiogenic inducer that it is activated by HIF-1 (a 
factor stabilized by hypoxia) is VEGF; a potent angiogenic inhibitor produced by RPE 
cells, that it is positively correlated with oxygen concentrations, is PEDF. 
[57]
 
Therefore, the aim of this study was to evaluate and characterize the expression levels 
of GLUT1 and angiogenic factors such VEGF and PEDF in models of DR both in vivo and 
in vivo models. 
In our in vitro studies we were able to demonstrate that the expression levels of GLUT1 
were increased in the cells cultured with medium containing glucose concentration 
simulating diabetes and subject to hypoxia. This increase was associated to an increase in 
GLUT1 in in the membrane of the cells. This means that hypoxia induces a translocation of 
the transporter to the membranes which was also described in early studies of the GLUT4 
in skeletal muscle. 
[81]
 
Regarding PEDF, we can say that in vitro there is no significant alteration in the 
expression levels comparing normoxia with hypoxia and normoglycemia with 
hyperglycemia. However it seems to have a tendency to decrease when D407 cells are 
exposed to hypoxia which is what we expected. One possible explanation is that D407 
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cells are a model of RPE and the RPE layer is the one of the major producer of PEDF that 
is secreted to act as neurotrophic and anti-angiogenic factor in the inner retina. This means 
that changes in PEDF levels may be more significant in the medium where they are 
released. 
[102]
  
Regarding VEGF, the in vitro results show a significant increase at the mRNA levels. 
However when we analyzed the protein levels we only saw an increase of VEGF 
expression in normoglycemic conditions when we compare normoxia with hypoxia and in 
normoxia conditions when we compare normoglycemia with hyperglycemia. This may 
result from the fact that immunochemistry and Western blot are qualitative methods and 
not quantitative methods like qPCR which may not detect small differences among tested 
conditions. 
Since VEGF is also a secreted factor that acts through VEGF receptors that are present 
in the membrane of the endothelial cells, it would be more accurate to analyze VEGF 
expression in the culture medium of the cells. For this reason the intracellular levels of 
VEGF may not alter significantly. 
In our in vivo models, our study shows some contradictory data. At 6 months of age, 
GLUT1 mRNA did not alter when comparing both strains but there is an increase of its 
protein in the retina of Ins2
Akita 
mice. This could result from the fact that at 6 months of age 
they are starting developing the disease which means that the increased of GLUT1 
expression is maybe due to an increase in translation and not in transduction. In contrast 
we found no differences in GLUT1 expression in the retina of 12 month-old Ins2
Akita
 mice, 
when compared with the age-matched non-diabetic control. In fact, some reports showed 
that at this age the retinal cells become senescent and there are more cell death events, 
which can explain our results. 
[93]
  
Similar results were verified for PEDF in vivo, where the mRNA levels did not show a 
significant difference between WT and Ins2
Akita
 mice at 6 and 12 months of age; however 
when we analyzed at the protein level there was a significant decrease of PEDF protein 
both retina and RPE of Ins2
Akita
 mice compared with WT at 6 months of age. These results 
are in agreement with Han et al. in which they also showed diminished PEDF protein 
expression in Ins2
Akita 
mice. 
[95]
 
For the older mice we can see by Western blot and immunohistochemistry analysis that 
there is no significant difference in PEDF protein levels in the retina of WT and Ins2
Akita
 
mice. However we found that there is no production of PEDF in the RPE of the 12 month-
Characterization of pro- and anti-angiogenic factors in models of Diabetic Retinopathy 
 
Liliana Alves                                                                              Masters in Biomedical Sciences 
  
50 
old Ins2
Akita
 mice, showing a marked influence of the time exposure to hyperglycemia in 
the maintenance of RPE function and PEDF production.  
Regarding VEGF, in this study we found a significant increase in the mRNA levels of 
VEGF between both strains at 6 months of age, which is in line with the literature. 
[95]
 
However there were no significant differences at the protein level. As it was proposed 
before, this may result from the diminished function of the translational machinery in 
hypoxic conditions. 
[79]
 At 12 months of age the only significant difference detected 
between strains was a decrease of its protein expression. This may be associated with the 
retinal ageing and senescence that is present at this age, which may be impaired the VEGF 
expression. 
[93] [101]
 
In conclusion, we could not see a clear correlation between PEDF and VEGF but we 
demonstrated a decrease of PEDF and an increase of GLUT1 that could be associated with 
the onset of the DR. 
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6. Future Perspectives  
DR remains the leading cause of blindness and visual impairment in the working age 
population. Research over the past few decades has identified many biochemical pathways 
that are associated with the pathophysiology of DR, but not a single one emerged as the 
sole responsible. Since a cure is the ultimate goal, these studies are important to better 
understand the disease and help develop a novel therapeutic that can ease the DR 
symptoms.  
Our work was focused on angiogenic factors, VEGF and PEDF, and Glut1, which may 
collectively be responsible for the onset of DR.  
In contrast to what we were expecting when we started to develop this work, we could 
not see a clear correlation between PEDF and VEGF in D407 cells or in in vivo models. 
Therefore, in the future we should try to use another in vitro model, such as human 
endothelial cells (HUVEC) that are the cells responsible for the majority of VEGF 
production. It would also be interesting to analyze the expression of both VEGF and PEDF 
in the supernatant of the cells in all the conditions tested before to see if there is any 
alteration on these secreted factors. Ideally we should also evaluate the expression of 
VEGF, PEDF and GLUT1 in Ins2
Akita
 with 9 months of age, since it was previously 
described that at this stage DR is already installed but not as severe as at 12 months, where 
we had most of the contradictory results. 
[95]
 
In the future we would like to analyze the expression of HIF-1α factor in those same 
conditions because HIF-1α is directly correlated with VEGF and GLUT1 and would be 
interesting to see their levels and correlate with these results. And if possible, increase the 
sample numbers for increased statistical significance.  
Taking into account some of the data like the increase in GLUT1 and the decrease of 
PEDF expression, we could in the future investigate therapies like the blockage/inhibition 
of GLUT1 or overexpression of PEDF and see if the phenotype is reversed on these mice. 
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8. Appendix 
Appendix 1: Table of real time qPCR Primers. 
Name Sequence Fragment 
hGLUT1_FW_RT TCACTGTGCTCCTGGTTCTG 
233 bp 
hGLUT1_Rev_RT CCTGTGCTCCTGAGAGATCC 
hPEDF_FW TAGACCGAGAACTGAAGACCG  
308 bp hPEDF_Rev TGTGTCTGTGTCCCTCAGTAC 
hPEDF_FW(2) TATCACCTTAACCAGCCTTTCATC 
83 bp 
hPEDF_Rev(2) GGGTCCAGAATCTTGCCAATG 
hPEDF_RT_FW(3) TATGACCTGTACCGGGTGCGA 
70 bp 
hPEDF_RT_Rev(3) CCACACTGAGAGGAGACAGGAGC 
hVEGF_FW ACTTCTGGGCTGTTCTCG  
141 bp hVEGF_Rev TCCTCTTCCTTCTCTTCTTCC 
hGAPDH_FW ACATCATCCCTGCCTCTACTG  
232 bp hGAPDH_Rev ACCACCTGGTGCTCAGTGTA 
hACTINβ_FW CATGTACGTTGCTATCCAGGC  
250 bp hACTINβ_Rev CTCCTTAATGTCACGCACGAT 
mGlut1_FW GCTGTGCTTATGGGCTTCTC  
114 bp mGlut1_Rev CACATACATGGGCACAAAGC 
mPedf_FW AATCACCCGACTTCAGCAAGA  
73 bp mPedf_Rev TCGAAAGCAGCCCTGTGTT 
mGapdh_FW GGTGAAGGTCGGTGTGAACG  
123 bp mGapdh_Rev ACCATGTAGTTGAGGTCAATGAAGG 
mActinβ_FW AGAGGGAAATCGTGCGTGAC  
138 bp mActinβ_Rev CAATAGTGATGACCTGGCCGT 
 
